Caladrius Biosciences - CLBS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $90.00
  • Forecasted Upside:
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Caladrius Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLBS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLBS

Analyst Price Target is $90.00
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Caladrius Biosciences in the last 3 months. The average price target is $90.00, with a high forecast of $90.00 and a low forecast of $90.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for CLBS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Caladrius Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2022HC WainwrightLower TargetBuy$120.00 ➝ $90.00Medium
11/5/2021HC WainwrightLower TargetBuy$150.00 ➝ $120.00Medium
6/22/2021Brookline Capital ManagementReiterated RatingBuyLow
3/3/2021Brookline Capital ManagementBoost TargetBuy$105.00 ➝ $150.00High
1/19/2021HC WainwrightReiterated RatingPositive ➝ Buy$277.50 ➝ $210.00High
5/25/2020Brookline Capital ManagementInitiated CoverageBuy$105.00High
5/18/2020Dawson JamesDowngradeBuy ➝ NeutralHigh
5/15/2020Chardan CapitalReiterated RatingBuy$90.00Low
5/8/2020HC WainwrightReiterated RatingBuy$277.50High
5/14/2019WBB SecuritiesInitiated CoverageSpeculative Buy$101.25High
5/12/2019Chardan CapitalReiterated RatingBuy$90.00Medium
2/27/2019Dawson JamesReiterated RatingBuyMedium
1/24/2019HC WainwrightReiterated RatingBuy$277.50Low
11/20/2018HC WainwrightInitiated CoverageBuy ➝ Buy$277.50High
9/10/2018HC WainwrightBoost TargetBuy$225.00High
8/29/2018Chardan CapitalReiterated RatingBuyHigh
6/6/2018HC WainwrightSet TargetBuy$180.00Low
5/11/2018HC WainwrightReiterated RatingBuy$180.00Medium
3/23/2018Chardan CapitalBoost TargetBuy ➝ Buy$97.50 ➝ $105.00High
3/14/2018HC WainwrightReiterated RatingBuy$180.00Low
3/6/2018HC WainwrightReiterated RatingBuy ➝ BuyHigh
1/19/2018HC WainwrightSet TargetBuy$105.00Low
(Data available from 12/5/2017 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2022
  • 5 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/6/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/5/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/5/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Caladrius Biosciences logo
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $6.37
Low: $0.43
High: $8.38

52 Week Range

Now: N/A

Volume

466,373 shs

Average Volume

522,308 shs

Market Capitalization

$26.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Caladrius Biosciences?

The following Wall Street analysts have issued research reports on Caladrius Biosciences in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for CLBS.

What is the current price target for Caladrius Biosciences?

1 Wall Street analysts have set twelve-month price targets for Caladrius Biosciences in the last year. Their average twelve-month price target is $90.00. HC Wainwright has the highest price target set, predicting CLBS will reach $90.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $90.00 for Caladrius Biosciences in the next year.
View the latest price targets for CLBS.

What is the current consensus analyst rating for Caladrius Biosciences?

Caladrius Biosciences currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLBS will outperform the market and that investors should add to their positions of Caladrius Biosciences.
View the latest ratings for CLBS.

What other companies compete with Caladrius Biosciences?

How do I contact Caladrius Biosciences' investor relations team?

Caladrius Biosciences' physical mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company's listed phone number is (908) 842-0100 and its investor relations email address is [email protected] The official website for Caladrius Biosciences is www.caladrius.com. Learn More about contacing Caladrius Biosciences investor relations.